Shumaila Tunio

Dr. Shumaila Tunio

University of Pikeville
+1

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
EWE. Whitlow
E. Whitlow
AMAbu Salim Mustafa
Abu Salim Mustafa
Shumaila TunioShumaila Tunio
Shumaila Tunio
Currently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette–Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and causes complications in immunocompromised individuals. Furthermore, it compromises the use of antigens present in the purified protein derivate of Mycobacterium tuberculosis in the diagnosis of TB. Many approaches, e.g., whole-cell organisms, subunit, and recombinant vaccines are currently being explored for safer and more efficacious TB vaccines than BCG. These approaches have been successful in developing a large number of vaccine candidates included in the TB vaccine pipeline and are at different stages of clinical trials in humans. This paper discusses current vaccination strategies, provides directions for the possible routes towards the development of new TB vaccines and highlights recent findings. The efforts for improved TB vaccines may lead to new licensed vaccines capable of replacing/supplementing BCG and conferring therapeutic value in patients with active/latent TB.

16 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
AHAnna Hargrave
Anna Hargrave
AMAbu Salim Mustafa
Abu Salim Mustafa
AHAsma Hanif
Asma Hanif
JTJaved H. Tunio
Javed H. Tunio
Shumaila TunioShumaila Tunio
Shumaila Tunio
HIV-1 infection and its progression to AIDS remains a significant global health challenge, particularly for low-income countries. Developing a vaccine to prevent HIV-1 infections has proven to be immensely challenging with complex biological acquisition and infection, unforeseen clinical trial disappointments, and funding issues. This paper discusses important landmarks of progress in HIV-1 vaccine development, various vaccine strategies, and clinical trials.

25 October 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
AHAnna Hargrave
Anna Hargrave
AMAbu Salim Mustafa
Abu Salim Mustafa
AHAsma Hanif
Asma Hanif
JTJaved H. Tunio
Javed H. Tunio
Shumaila TunioShumaila Tunio
Shumaila Tunio
Cancer immunotherapies refer to the concept of retraining the immune system to target malignant cells. Multiple immunotherapeutic options exist including immune modulating antibodies, immune stimulating cytokines, chimeric antigen receptor T cell therapy, and vaccines. Overall, this field has advanced rapidly as knowledge of the tumor microenvironment, immunological pathways, and biotechnology expands. Specifically, advancements in neoantigen identification, characterization, and formulation into a vaccine show promise. This review is focused on previously United States Food and Drug Administration-approved cancer therapeutic vaccines and neoantigen-based vaccine developments along with the associated relevant clinical trials.

1 January 2012 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
Shumaila TunioShumaila Tunio
Shumaila Tunio
Lucila Garcia-ContrerasLucila Garcia-Contreras
Lucila Garcia-Contreras
Historically, pharmaceutical aerosols have been employed for the treatment of obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease, but in the past decades their use has been expanded to treat lung infections associated with cystic fibrosis and other respiratory diseases. Tuberculosis (TB) is acquired after inhalation of aerosol droplets containing the bacilli from the cough of infected individuals. Even though TB affects other organs, the lungs are the primary site of infection, which makes the pulmonary route an ideal alternative route to administer vaccines or drug treatments. Optimization of formulations and delivery systems for anti-TB vaccines and drugs, as well as the proper selection of the animal model to evaluate those is of paramount importance if novel vaccines or drug treatments are to be successful. Pharmaceutical aerosols for patient use are generated from metered dose inhalers, nebulizers and dry powder inhalers. In addition to the advantages of providing more efficient delivery of the drug, low cost and portability, pharmaceutical dry powder aerosols are more stable than inhalable liquid dosage forms and do not require refrigeration. Methods to manufacture dry powders in respirable sizes include micronization, spray drying and other proprietary technologies. Inhalable dry powders are characterized in terms of their drug content, particle size and dispersibility to ensure deposition in the appropriate lung region and effective aerosolization from the device. These methods will be illustrated as they were applied for the manufacture and characterization of powders containing anti-tubercular agents and vaccines for pulmonary administration. The influence of formulation, selection of animal model, method of aerosol generation and administration on the efficacy demonstrated in a given study will be illustrated by the evaluation of pharmaceutical aerosols of anti-TB drugs and vaccines in guinea pigs by our group.

20 July 2010 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Shumaila TunioShumaila Tunio
Shumaila Tunio
RAR. Al-Attiyah
R. Al-Attiyah
AMAbu Salim Mustafa
Abu Salim Mustafa